Prothena: Delays And Data Uncertainty Undermine Case For Investing (Downgrade) [Seeking Alpha]
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Seeking Alpha
Investing Group Leader Follow Play 16min Summary Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful Phase 1 data for PRX012. PRX012, targeting amyloid beta for Alzheimer's, is Prothena's key value driver but remains in Phase 1, lagging competitors with similar drugs. Birtamimab's Phase 3 data has also faced delays, and while promising, it competes in a crowded market with limited patient populations. Despite a strong cash position, Prothena's pipeline progress and competitive landscape justify a downgrade to “Hold” until more substantial data is available. PeopleImages/E+ via Getty Images Investment Overview I last covered Prothena Corporation plc NASDAQ: PRTA ) in a note for Seeking Alpha in September 2023, upgrading my former “Hold” rating on the stock to a “Buy.” That proven to be an unwise decision, as Prothena If you like what you have just read and want to receive at least 4 exclu
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]Seeking Alpha
- Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
PRTA
Earnings
- 11/12/24 - Beat
PRTA
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- 11/13/24 - Form SC
- PRTA's page on the SEC website